Using PAK4 as a therapeutic target in an in vivo mouse model with PaCa using exosome-mediated intra-tumor administration has been shown to reduce the growth of PaCa cells and improve survival rate in mice (p < 0.001) [91]. The gene discussed is PAK4; the disease is permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.